• / Free eNewsletters & Magazine
  • / My Account
Home>Antibody Humanization and Affinity Maturation Markets 2017-2030 - Focus on Services and Platforms - Research and Markets

Antibody Humanization and Affinity Maturation Markets 2017-2030 - Focus on Services and Platforms - Research and Markets

Antibody Humanization and Affinity Maturation Markets 2017-2030 - Focus on Services and Platforms - Research and Markets

09/29/2017

Antibody Humanization and Affinity Maturation Markets 2017-2030 - Focus on Services and Platforms - Research and Markets

The "Antibody Humanization and Affinity Maturation: Services and Platforms, 2017-2030" report has been added to Research and Markets' offering.

The "Antibody Humanization and Affinity Maturation: Services and Platforms, 2017-2030" report provides a comprehensive view on the current landscape and the future outlook of the antibody humanization and affinity maturation contract research services and platforms market. The study presents an in-depth analysis of a diverse set of companies that provide such services across different regions worldwide.

In the year 2016, Humira, a monoclonal antibody, generated revenues worth more than USD 16 billion to become the highest selling drug. With a strong development pipeline and high clinical success rate, the market continues to witness increasing adoption of antibody based therapies and products.

The growing industry has faced/continues to face several challenges. One of the biggest hurdles to the growth of antibody based products has been the lack of technical know-how across different stages of drug discovery. This situation is particularly true for the more traditional pharmaceutical companies that have recently ventured into the targeted therapies domain.

Some of these companies have mitigated this issue by making specific acquisitions and/or hiring trained personnel to cater to the requirements. However, several others have preferred to out-source these steps to contract services providers. In fact, over the years, a number of services providers offering antibody discovery have been established, and have grown to become an indispensable part of the biopharmaceutical market.

Certain steps of the antibody drug discovery process require advanced expertise, and companies offering these specialized services have attracted significant attention of drug/therapy developers. Two such specific services are to reduce antibody immunogenicity (humanization) and enhance its affinity (affinity maturation). Immunogenicity has continued to be one of the most limiting factors of the clinical success of antibodies.

Antibody humanization has emerged as an extensively studied method for reducing antibody immunogenicity. There are several contract services providers that are providing novel technologies beyond the traditional methods to facilitate antibody humanization as well as to enhance antibody affinity. These contract services providers have enabled the drug developers to develop therapeutic antibodies with low immunogenicity and high affinity.

©2017 Morningstar Advisor. All right reserved.